Biologic therapy in inflammatory bowel disease

In luminal Crohn's disease with moderate to severe inflammatory activity, infliximab and adalimumab can be used in the case of treatment failure with conventional therapies, such as systemic steroids and immunosuppressive therapy or if this treatment is not tolerated. Further treatment strategy...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Danish medical journal 2013-06, Vol.60 (6), p.B4652-B4652
Hauptverfasser:	Theede, Klaus, Dahlerup, Jens Frederik, Fallingborg, Jan, Hvas, Christian Lodberg, Kjeldsen, Jens, Munck, Lars Kristian, Nordgaard-Lassen, Inge
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Biological Therapy Humans Inflammatory Bowel Diseases - drug therapy Infliximab Severity of Illness Index
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!